Ribo Newsroom

Suzhou Ribo Life Science Co., Ltd. has announced the successful completion of two phase II clinical trials of ISIS 449884, an antisense oligonucleotide（ASO）drug for treatment of Type 2 Diabetes Mellitus (T2DM).

Ribo Life Science Co., Ltd. (Ribo) recently announced the completion of "A randomized, double-blind, placebo-controlled, single-dose escalating Phase I clinical study to evaluate the safety and pharmacokinetics of RBD1016 in healthy subjects" of its Class 1 siRNA drug for chronic hepatitis B in Australia.

On Nov. 19, MIT Technology Review unveiled its list of "50 Smartest Companies" (TR50) of 2020 in Suzhou, China. Thanks to the innovative breakthroughs in oligonucleotide therapeutics, Ribo was shortlisted as a manufacturer of innovative drugs and listed as a TR50 smart company.

Suzhou Ribo Life Science Co., Ltd. has recently obtained an implied license for clinical trials of its innovative ASO drug ISIS 560131, which had been introduced and developed by Ribo, following review by the Center for Drug Evaluation under the National Medical Products Administration.

Suzhou Ribo Life Science Co., Ltd. announced today that 470 million yuan was raised during its Series C2 financing. In this round of financing, the lead investors included China Venture Capital Fund Corporation Ltd., CICC Qide Fund, and GL Ventures, and the co-investors included renowned investment institutes such as Hengxu Capital, Everest VC, Sin

On December 5, 2019, Suzhou Ribo Life Science Co. Ltd., announced the successful completion of Series C1 financing worth RMB 203 million.